Pluristem Therapeutics Receives DSMB Approval to Advance to Final Dose Level With PLX-PAD

HAIFA, Israel, March 2, 2010 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (DAX:PJT) today announced that it has received approval from an independent Data Safety Monitoring Board (DSMB) to advance to the highest and final dose level with its placenta-derived cell therapy product, PLX-PAD, in a Phase I dose-escalating clinical trial in Europe for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).

Back to news